FridayJun 14, 2024 9:45 am

Astrotech Corp. (NASDAQ: ASTC) Expands Role of Mass Spectrometry in Industrial Processes

In the chemical manufacturing industry, innovative uses of mass spectrometry are a game-changer by ensuring quality control, increased yields, and increased profits Astrotech subsidiary, Pro-Control Inc., has positioned its product line between the need for the chemical manufacturers to offset lower prices with efficiency gains that could offset potential losses The Pro-Control Maximum Value Processing(TM) can perform in-situ process tests every 5 minutes greatly increasing efficiency across a wide range of chemical manufacturing processes Mass spectrometry (“MS”) is becoming a transformative analytical technique that has revolutionized how materials are tested and processed in various industries, such as petrochemical. The supreme…

Continue Reading

FridayJun 14, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Therapies Targeting Neurodegenerative Diseases

INM is advancing INM-089 targeting age-related macular degeneration and INM-901 targeting Alzheimer’s disease The company recently posted positive results for INM-089 demonstrating significant functional and pathological improvements in an AMD disease model Recent preclinical data for INM-901 displayed positive pharmacological effects for treating Alzheimer's disease INM posted a business update for Q3-2024 reporting a closing cash position of US$7.9 million and revenue growth for subsidiary BayMedica, a supplier of rare cannabinoids as ingredients InMed Pharmaceuticals (NASDAQ: INM), a is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s…

Continue Reading

TuesdayJun 11, 2024 10:30 am

HealthLynked Corp. (HLYK) CEO Provides $1 Million Financing to Speed Company’s Continued Success in Revolutionizing Healthcare Industry

HealthLynked CEO Dr. Michael Dent recently provided $1 million in financing to the company, expected to accelerate its growth and expand its offerings Under Dr. Dent’s leadership, the company has developed an expansive array of products and services, including a comprehensive healthcare platform that connects patients, healthcare providers, and medical facilities in a secure, more efficient and cost-effective manner The company’s services include online medical records storage, online appointment scheduling for doctors nationwide, telemedicine, patient engagement tools, an e-commerce platform for over 15,000 name-brand medical supplies, concierge patient support, nurse chat, a reward points program, and co-management of family members’…

Continue Reading

MondayJun 10, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Is ‘One to Watch’

Recent Achievements Annovis Bio recently announced statistically significant data from its Phase II/III Alzheimer’s study, showcasing Buntanetap’s potential to improve cognition in patients with mild AD Annovis Bio recently announced last patient last visit in the Phase III study of Buntanetap in patients with early Parkinson’s disease and expects data announcement in June 2024, marking significant progress in expanding its therapeutic reach The company has solidified strategic partnerships to enhance its research capabilities and broaden its market reach Investment Considerations Unique Market Position: Annovis Bio is the only company developing a drug for both AD and PD that inhibits multiple neurotoxic…

Continue Reading

WednesdayJun 05, 2024 10:30 am

Astrotech Corp. (NASDAQ: ASTC) Subsidiary, “1st Detect”, Focuses on Superior Narcotics Trace Detection For Airport and Other Security Sites

Astrotech Corporation Subsidiary 1st Detect Approved as GSA Vendor; Introduces Advanced Narcotics Trace Detection Technology 1st Detect has now received approval from the U.S. General Services Administration (“GSA”) as an authorized vendor for government-related applications 1st Detect recently introduced a state-of-the-art Narcotics Trace Detection (“NTD”) narcotics library, which is particularly useful for detection at points of entry and government agencies involved in combating the illicit drug trade 1st Detect's portfolio now includes the TRACER 1000, Explosives Trace Detection (“ETD”) and Narcotics Trace detection Astrotech (NASDAQ: ASTC), through its subsidiary 1st Detect, is revolutionizing narcotics and explosives trace detection. With recent…

Continue Reading

TuesdayJun 04, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Announces Updates on ACT-EAP for CNM-Au8(R) Compassionate Use

Clene announced significant updates to their NIH-funded Accelerating Access to Critical Therapies Expanded Access Program (ACT-EAP) for CNM-Au8(R) compassionate use in amyotrophic lateral sclerosis (“ALS”) Clene has optimized its manufacturing, operational, and personnel processes to expand the program’s capacity to accommodate up to 180 participants The ACT-EAP, a collaboration among Clene, Columbia University, and Synapticure, was funded by the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS), signed into law by Congress and President Biden in December 2021 Clene (NASDAQ: CLNN) and its subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to improving mitochondrial health and protecting…

Continue Reading

MondayJun 03, 2024 8:45 am

HealthLynked Corp. (HLYK) Continues to Expand AI Capabilities

HealthLynked is at the forefront of revolutionizing global healthcare related solutions for patients, doctors, and related healthcare organizations Some of the company’s solutions, including the HealthLynked Network, Augmented Real-Time Interface, and the new AI chat feature, incorporate artificial intelligence capabilities to foster better patient outcomes for all The new AI chat feature is designed to assist patients in locating healthcare providers across the country using markers such as name, specialty, or location and significantly enhance the effectiveness of the HealthLynked Concierge Team in reducing wait times and offering 24/7 service to users HealthLynked continues to lead in the development of…

Continue Reading

WednesdayMay 29, 2024 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) Shares Corporate Update and Commitment to Advancing Therapies for Neurological Disorders, Prepares for Key Engagements with the FDA

PaxMedica is preparing to submit a New Drug Application to the U.S. Food and Drug Administration later this year for using suramin to treat Human African Trypanosomiasis PaxMedica is currently preparing for an associated and very important Type C meeting with the FDA scheduled for June 27th Type C meetings are designated by the FDA to address specific issues in drug development, such as clinical trial design, data requirements, or other scientific matters not covered by Type A or Type B meetings PaxMedica (NASDAQ: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, recently shared corporate updates regarding its continued…

Continue Reading

FridayMay 24, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Participates in Three Investor Conferences During May 2024, Promoting CNM-Au8(R) Neuronal Health Therapy

Clene recently participated in the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference CNM-Au8(R) is oral suspension developed to restore neuronal health and function by increasing energy production and utilization The therapy has been involved in clinical trials and compassionate use programs, accumulating over 600 years of exposure across various neurodegenerative conditions, with no safety concerns reported Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease, recently…

Continue Reading

FridayMay 24, 2024 9:00 am

PaxMedica Inc. (NASDAQ: PXMD) Seeking to Qualify for Neglected Tropical Disease Priority Review Voucher Program in Wake of Malawi Major Sleeping Sickness Crisis

PaxMedica has received an urgent plea from the Ministry of Health of Malawi for emergency access to IV suramin to prevent a potential humanitarian crisis due to dwindling supplies of essential drugs used to save lives in the region PaxMedica has previously concluded a Type B meeting with the FDA in preparation for the NDA submission, focusing on the use of PAX-101 in treating the rare and fatal trypanosomal infection, Trypanosoma brucei rhodesiense, transmitted by tsetse flies PaxMedica also aims to potentially qualify for a Priority Review Voucher under the Neglected Tropical Disease Priority Review Voucher Program, which could provide…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000